Eye Drug is Effective in Treating Diabetic RetinopathyTuesday, November 17, 2015
Funded by the National Eye Institute (NEI) and conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net), the trial compared Lucentis injections with a type of laser therapy called panretinal photocoagulation, which has remained the gold standard for PDR since the mid-1970s. Although laser therapy preserves central vision, it can damage night and side vision, so researchers have sought therapies that lack these side effects.
The trial results "provide crucial evidence for a safe and effective alternative to laser therapy against PDR," says NEI Director Paul A. Sieving, MD, PhD.
"Patients who received Lucentis showed a little bit better central vision, much less loss of their side vision, and substantially less risk for surgery than patients who received laser treatment," states Lloyd Paul Aiello, MD, PhD, director of the Beetham Eye Institute at Joslin Diabetes Center and Professor of Ophthalmology at Harvard Medical School. "These findings will change the available treatment options for patients with PDR."
Diabetic retinopathy damages blood vessels in the light-sensitive retina in the back of the eye. As the disease worsens, blood vessels can swell and lose their ability to function properly. Diabetic retinopathy becomes proliferative when lack of blood flow in the retina increases production of a protein called vascular endothelial growth factor (VEGF), which can stimulate the growth of new, abnormal blood vessels. These new vessels are prone to bleeding into the center of the eye, sometimes requiring a surgical procedure called a vitrectomy to clear the blood. The abnormal blood vessels can also cause scarring and retinal detachment. Untreated, PDR is associated with high risk of visual loss. Lucentis is among several drugs that block the effects of VEGF.
Dr. Aiello and George King, MD, Chief Scientific Officer at Joslin Diabetes Center and Professor of Medicine at Harvard Medical School, pioneered the study of VEGF in diabetic eye disease, beginning in the early 1990s. (Their work followed a distinguished Joslin tradition--the basic laser photocoagulation technique was developed in the 1960s by Dr. Aiello's father, Lloyd M. Aiello, MD, and grandfather, William P. Beetham, M.D.)
About 7.7 million U.S. residents have diabetic retinopathy, a leading cause of blindness among working-age Americans. Among these, about 1.5 percent have progressed to PDR.
The DRCR.net enrolled 305 participants (394 eyes) with PDR in one or both eyes at 55 clinical sites across the country. Eyes were assigned randomly to treatment with Lucentis or laser. About half of the eyes assigned to the laser group required more than one round of laser treatment. In the other group, Lucentis was injected into the eye once per month for three consecutive months, and then as needed until the disease resolved or stabilized.
Because Lucentis is commonly injected to treat diabetic macular edema (DME)--a build-up of fluid in the center of the retina--the study permitted the use of Lucentis for DME in the laser group, if necessary. Slightly more than half (53 percent) of eyes in the laser group received Lucentis injections to treat DME. About 6 percent of eyes in the Lucentis group received laser therapy, mostly for issues other than DME.
At two years, vision in the Lucentis group improved by an average of about half a line on an eye chart, compared with virtually no change in the laser group.
Source: Joslin Diabetes Center